Patent EP0631137A2 successfully refreshed from Google Patents.
EP0631137A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Glucose related measurement method and apparatus
Assignee: Individual
•
Filing: 1994-05-31
•
Granted: —
•
Expires: 2014-05-31
Abstract
Abstract A method of and apparatus for determining stable and labile glycated compound levels in blood. Electromagnetic energy covering a multiplicity of wavelength bands within a wavelength range from 380 nm to 2500 nm is directed into a sample volume containing blood. Portions of the energy representative of both the source energy and energy after interacting with material within the sample volume are collected. The energy portions carry information relating to the source energy and the levels of labile and stable compounds within the sample volume, respectively. The portions are converted into electrical signals representative of the intensities of the respective portions in each of the multiplicity of wavelength bands. The electrical signals are pretreated in accordance with known information to remove deviations from established reference conditions to form data signals that are a function of the fractional portion of the energy in each of the wavelength bands absorbed and scattered by the material in the measurement volume. Selected groups of the data signals are processed in accordance with chemometric models developed from analysis of such data signals together with known values of the analytes derived from measurements on a calibration set of samples larger in number than the number of wavelength bands included in the set of the selected groups of data signals to develop analyte signals representative of the amounts of glycated compounds for which chemometric models have been developed and utilized. The analyte signals may be stored and displayed in a form suitable for medical use.
Inventors
- 👤 Edward W. Stark
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-10 02:05
CPC Classifications
G; G01; G01N; G01N21/00; G01N21/17; G01N21/25; G01N21/31; G01N21/314; A; A61; A61B; A61B5/00; A61B5/145; A61B5/14532; A61B5/1455; Y; Y10; Y10T; Y10T436/00; Y10T436/14; Y10T436/142222; Y10T436/143333; Y10T436/144444
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
290 words
A method of determining stable and labile glycated compound levels in blood comprising the steps of: a) supplying a source of electromagnetic energy covering a multiplicity of wavelength bands within a wavelength range from 380 nm to 2500 nm; b) directing the electromagnetic energy from said source into a sample volume containing blood; c) collecting a first portion of said energy representative of said source energy; d) collecting a second portion of said energy after it has interacted with material within said sample volume, said second portion carrying information relating to the levels of labile and stable glycated compounds within said sample volume; e) converting said first portion into first electrical signals representative of intensity of said first portions in each of said multiplicity of wavelength bands; f) converting said second portion into second electrical signals representative of intensity of said second portion in each of said multiplicity of wavelength bands; g) pretreating said electrical signals in accordance with known information to remove deviations from established reference conditions to form data signals that are a function of the fractional portion of the energy in each of said wavelength bands absorbed and scattered by said material in said measurement volume; h) processing selected groups of said data signals in accordance with chemometric models developed from analysis of such data signals together with known values of the analytes derived from measurements on a calibration set of samples larger in number than the number of wavelength bands included in the set of said selected groups of data signals to develop analyte signals representative of the amounts of glycated compounds for which chemometric models have been developed and utilized; and, i) storing and displaying said analyte signals in a form suitable for medical use.
Claim 2
Dependent Claim
70 words
The method of claim 1 further comprising the step of extracting from said data signals a reference signal representative of a temporal waveform of a portion of the data signals derived from the blood and processing each of the data signals representing different wavelength bands in accordance with said reference signal to derive blood data signals representative of the portion of the energy absorbed or scattered by the blood alone.
Claim 3
Dependent Claim
80 words
The method of claim 1 or 2 wherein said pretreating step comprises a method for correcting for stray light and optical/electronic crosstalk, said method for correcting comprising the steps of: a) measuring all data signals at each energy wavelength band; b) generating a response factor matrix R; c) calculating corrected signal data, S',using the following equation: S' = SR⁻¹ where R⁻¹ is the inverse of the response factor matrix R and S is a vector expressing the measured data signal.
Claim 4
Independent Claim
17 words
The method of any of claims 1 to 3 wherein said electromagnetic energy comprises a pulse waveform.
Claim 5
Independent Claim
28 words
The method of any of the claims 1 to 4 wherein said glycated compound is labile hemoglobin and said wavelength range being from 520 nm to 620 nm.
Claim 6
Independent Claim
303 words
An apparatus for determining stable and labile glycated compound levels in blood which comprises: a) a source of electromagnetic energy covering a multiplicity of wavelength bands within a wavelength range from 380 nm to 2500 nm; b) means for directing the electromagnetic energy from said source into a sample volume containing blood; c) means for collecting a first portion of said energy representative of said source energy; d) means for collecting a second portion of said energy after it has interacted with material within said sample volume, said second portion carrying information relating to the levels of labile and stable glycated compounds within said sample volume; e) means for converting said first portion into first electrical signals representative of intensity of said first portions in each of said multiplicity of wavelength bands; f) means for converting said second portion into second electrical signals representative of intensity of said second portion in each of said multiplicity of wavelength bands; g) means for pretreating said electrical signals in accordance with known information to remove deviations from established reference conditions to form data signals that are a function of the fractional portion of the energy in each of said wavelength bands absorbed and scattered by said material in said measurement volume; h) means for processing selected groups of said data signals in accordance with chemometric models developed from analysis of such data signals together with known values of the analytes derived from measurements on a calibration set of samples larger in number than the number of wavelength bands included in the set of said selected groups of data signals to develop analyte signals representative of the amounts of glycated compounds for which chemometric models have been developed and utilized; and, i) means for storing and displaying said analyte signals in a form suitable for medical use.
Claim 7
Dependent Claim
70 words
The apparatus of claim 6 which further comprises means for extracting from said data signals a reference signal representative of a temporal waveform of a portion of the data signals derived from the blood and processing each of the data signals representing different wavelength bands in accordance with said reference signal to derive blood data signals representative of the portion of the energy absorbed or scattered by the blood alone.
Claim 8
Dependent Claim
69 words
The apparatus of claim 6 or 7 wherein said means for pretreating comprises: a) means for measuring all data signals at each energy wavelength band; b) means for generating a response factor matrix R; c) means for calculating corrected signal data, S',using the following equation: S' = SR⁻¹ where R⁻¹ is the inverse of the response factor matrix R and S is a vector expressing the measured data signal.
Claim 9
Independent Claim
17 words
The apparatus of any of claims 6 to 8 wherein said electromagnetic energy comprises a pulse waveform.
Claim 10
Independent Claim
27 words
The apparatus of any of claims 6 to 9 wherein said glycated compound is labile hemoglobin and said wavelength range being from 520 nm to 620 nm.
Claim 11
Independent Claim
279 words
A method of directly measuring glucose levels in blood comprising the steps of: a) supplying a source of electromagnetic energy covering a multiplicity of wavelength bands within a wavelength range from 380 nm to 2500 nm; b) directing the electromagnetic energy from said source into a sample volume containing blood; c) collecting a first portion of said energy representative of said source energy; d) collecting a second portion of said energy after it has interacted with material within said sample volume, said second portion carrying information relating to the glucose levels within said sample volume; e) converting said first portion into first electrical signals representative of intensity of said first portions in each of said multiplicity of wavelength bands; f) converting said second portion into second electrical signals representative of intensity of said second portion in each of said multiplicity of wavelength bands; g) pretreating said electrical signals in accordance with known information to remove deviations from established reference conditions to form data signals that are a function of the fractional portion of the energy in each of said wavelength bands absorbed and scattered by said material in said measurement volume; h) processing selected groups of said data signals in accordance with chemometric models developed from analysis of such data signals together with known values of the analytes derived from measurements on a calibration set of samples larger in number than the number of wavelength bands included in the set of said selected groups of data signals to develop analyte signals representative of glucose levels for which chemometric models have been developed and utilized; and, i) storing and displaying said analyte signals in a form suitable for medical use.
Claim 12
Dependent Claim
70 words
The method of claim 11 further comprising the step of extracting from said data signals a reference signal representative of a temporal waveform of a portion of the data signals derived from the blood and processing each of the data signals representing different wavelength bands in accordance with said reference signal to derive blood data signals representative of the portion of the energy absorbed or scattered by the blood alone.
Claim 13
Dependent Claim
80 words
The method of claim 11 or 12 wherein said pretreating step comprises a method for correcting for stray light and optical/electronic crosstalk, said method for correcting comprising the steps of: a) measuring all data signals at each energy wavelength band; b) generating a response factor matrix R; c) calculating corrected signal data, S',using the following equation: S' = SR⁻¹ where R⁻¹ is the inverse of the response factor matrix R and S is a vector expressing the measured data signal.
Claim 14
Independent Claim
20 words
The method of any of claims 11 to 13 wherein said wavelength range is from 1110 nm to 1560 nm.
Claim 15
Dependent Claim
13 words
The method of claim 14 wherein said electromagnetic energy comprises a pulse waveform.
Claim 16
Dependent Claim
20 words
The method of claim 15 wherein said pulse waveform is derived from a signal having a wavelength below 1110 nm.
Claim 17
Independent Claim
293 words
An apparatus for directly measuring glucose levels in blood which comprises: a) a source of electromagnetic energy covering a multiplicity of wavelength bands within a wavelength range from 380 nm to 2500 nm; b) means for directing the electromagnetic energy from said source into a sample volume containing blood; c) means for collecting a first portion of said energy representative of said source energy; d) means for collecting a second portion of said energy after it has interacted with material within said sample volume, said second portion carrying information relating to the glucose levels within said sample volume; e) means for converting said first portion into first electrical signals representative of intensity of said first portions in each of said multiplicity of wavelength bands; f) means for converting said second portion into second electrical signals representative of intensity of Said second portion in each of said multiplicity of wavelength bands; g) means for pretreating said electrical signals in accordance with known information to remove deviations from established reference conditions to form data signals that are a function of the fractional portion of the energy in each of said wavelength bands absorbed and scattered by said material in said measurement volume; h) means for processing selected groups of said data signals in accordance with chemometric models developed from analysis of such data signals together with known values of the analytes derived from measurements on a calibration set of samples larger in number than the number of wavelength bands included in the set of said selected groups of data signals to develop analyte signals representative of the glucose levels for which chemometric models have been developed and utilized; and, i) means for storing and displaying said analyte signals in a form suitable for medical use.
Claim 18
Dependent Claim
70 words
The apparatus of claim 17 which further comprises means for extracting from said data signals a reference signal representative of a temporal waveform of a portion of the data signals derived from the blood and processing each of the data signals representing different wavelength bands in accordance with said reference signal to derive blood data signals representative of the portion of the energy absorbed or scattered by the blood alone.
Claim 19
Dependent Claim
69 words
The apparatus of claim 17 or 18 wherein said means for pretreating comprises: a) means for measuring all data signals at each energy wavelength band; b) means for generating a response factor matrix R; c) means for calculating corrected signal data, S',using the following equation: S' = SR⁻¹ where R⁻¹ is the inverse of the response factor matrix R and S is a vector expressing the measured data signal.
Claim 20
Independent Claim
73 words
An apparatus for correcting data signals for stray light and optical/electronic crosstalk at energy wavelength the band comprising: a) means for measuring said data signals at energy wavelength bands; b) means for generating a response factor matrix R; c) means for calculating corrected signal data, S',using the following equation: S' = SR⁻¹ where R⁻¹ is the inverse of the response factor matrix R and S is a vector expressing the measured data signal.
Claim 21
Independent Claim
70 words
A method for correcting for stray light and optical/electronic crosstalk, said method for correcting comprising the steps of: a) measuring said data signals at a plurality of energy wavelength bands; b) generating a response factor matrix R; c) calculating corrected signal data, S',using the following equation: S' = SR⁻¹ where R⁻¹ is the inverse of the response factor matrix R and S is a vector expressing the measured data signal.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.